biotech may get crushedif we continue this bear reversal in biotech labd may cross signal and estimate bull and reach for upper envelope in a reverse head and shouldern pattern. if we carve a path higher in major indices i expect biotech to follow.
Biotech-etf
$XBI Key Levels, Analysis & Targets - Request$XBI Key Levels, Analysis & Targets - Request
Ok, @FlashingGraphs so these would be my targets fo XBI. It sounds like you don’t have an open position yet… I would start around 78.06.
Then if it keeps selling off, then double your position at 62.94
And if it still continues then double again at 45.89. If those 3 hit then you can expect a solid 50% swing from there…
Because of the way the Biotech sector moved in the past two years I could definitely see it making a 3 standard deviation move down like this, in correction. Don’t go in too heavy until you see a clear reversal sign… (such as macD crossing back above 0, and consistent higher lows)
And with that being said I still would start building from Target 1. I hope this helps.
GL & happy swinging…
JAGX Signs Second Agreement for $6 Mil Non-dilutive FinanciningJaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
Jaguar Health, Inc. has signed an agreement (the "Agreement") with a secured lender (the "Lender") for a non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the Lender for an aggregate purchase price of $6 million (the "Royalty Purchase Price") a royalty interest entitling the Lender to receive 2.0x the Royalty Purchase Price of future royalties of Mytesi® (crofelemer) and lechlemer and certain up-front license fees and milestone payments from licensees and/or distributors as well as any interest, fees, and charges in accordance with the terms set forth in the Agreement (the "Royalty Repayment Amount"), and to pay interest on the Royalty Repayment Amount at the rate of ten percent per annum until the same is paid in full.
No royalty payments due for 18-24 months
Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline
This $6 million royalty financing transaction follows an earlier $6 million royalty transaction consummated in October 2020 with an affiliate of the Lender.
We may consider entering into similar agreements in the future and of course business development relationships as additional sources of non-dilutive funding."
finance.yahoo.com
Biotech's Lookin' Good (for a bit at least)Bull flag that looked for a short while like it was pulling a head-fake and retreating but in the last hour of trading (as always) my instincts are rewarded and it continues to climb up. I've put in a prospective overhead resistance but remember to trail your stops because anything can happen! Other ETF's are looking bullish too like DRN, SOXL and TECL.
Long Biotech for Multi-Year CycleIBB looks to have a just broken out of a 5 year basing pattern. The longer the base, the higher in space. I'm going long 3-5 year hold with sell target of >$400.
LABD: Bearish on biotech tomorrowI don't know how other people are feeling but there are a lot of bearish declining wedges appearing in the leveraged ETFs and elsewhere. Makes me wonder what news we're getting between now and then.
Trade idea #BTK long on a break of the 5450 levelBiotechnology belongs to the sectors of the stock market which were rather moderately affected by the Coronacrisis. In fact, in the second half of april the NYSE ARCA Biotechnology Index even managed to surpass its pre-corona levels to attack its previous high at about 5.420. However the advance of the preceding days was too strong to get beyond that level and in line with the total market the index got rejeceted at that resistance level.
Looking now at the weekly chart a multi-month range between 3850 and 5450 can be seen which followed a previous advance of the index. Trend trader would now expect the index to pass the upper boundary of that range but we have to patiently wait if that will happen or if the index will continue to trade within that range.
For a long breakout trade the following trading strategies are possible:
a/ set a buy stop order > 5.550 (upper boundary at 5.450 + 2% )
b/ go long on a daily close > 5.450
c/ go long on a weekly close > 5.450 (unless price gets too far away from the 5450 handle)
d/ after a successfull breakout wait for a consolidation back to the 5450 level to look for a Long entry
Which strategy you use depends of course on your trading style. Also a combination of the 4 strategies could make sense, i.e. 33% for a/, 17% for b/, 17% for c/ and 33% for d/.
Stop loss should be the last swing low. If the index won't take out last week's low this would be 4.950, otherwise the stop must be adjusted.
A first target for 50% of the position could be set at the round figure of 7.000.
I will update on the trade idea. See you.
Biotech Sector bullish channelThere is a good RRR to enter XBI today. We seem to be in a bullish channel (showed in chart).
IMMU - Which is 1.5% of the sector, is also a good option. (higher risk - higher reward).
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as
INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.
“FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.”
The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races.
“We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.”
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products.
Forward-Looking Statements
This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
XBI global rout imminentThere's major global pull back, Biotechnology will scale back, but not as much as SP500 and DOW.
You should hedge properly, VIX will be back soon.
*Election year is Biotech Year*
pennies to thousands etf out of cloud candidatemacd crossed above cloud above key ma
get on book that takes our indicators to buy efts 40 years experience know exit and entry rules
bollinger bands widening relative strength strong
cci and percent r upper range
Possible turning point for BiotechIBB (Bio Tech ETF) had been on down turn since the last hurrah in July.
It has been doing a beautiful correction A B C waves - currently at the end of wave (c) of C.
Wave A is a double 0.5 X 1 move of the Gann Box
Wave B is a 1.272 X 0.5 of the first Gann box.
Wave C so far has been a 0.5 X 0.766 (although it might end up at 0.618 and 0.886 or 1)
This movements are a perfect sample of alternating deep move short time - and shallow move long time ( A concept that I learn from Andrew Long).
And since the move align perfectly to Fibonacci lines - I am giving my salut to one of the greatest mind in technical analysis WD Gann - GANN ROCKS.
The price is in the middle of the side-way move after a hammer candle.
While yesterday hammer might be the end if wave (c), it might still have some down waves. moving from the current position or going to the targets at 244 or 207 before turning up.
A confirmation that the end of wave (c) is taken is needed before entering LONG
Target entry is a fib above the end points.
Potential target exit is on the green circles.
Since this is my first posting, I would like to thank these people always patient to answer my questions and encourage me to do my first posting - BM from WallStScalper, DaftSimon, and MikeSer .
Last but not least, my utmost appreciation to my mentor - the amazing - Andrew Long from www.triggers.ca who teaches me the HPTZ Method that I use to make this chart.
